Predictability of Adjuvant Trastuzumab Benefit in N9831 Patients Using the ASCO/CAP HER2-Positivity Criteria
- Citation:
- J Natl Cancer Inst vol 104 (2) 159-162
- Year:
- 2012
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- 1
- Parents:
- 530
- Children:
- None
- Pharmas:
- Grants:
- CA114740, R01CA129949, U10CA25224
- Corr. Author:
- Authors:
- Edith A. Perez Amylou C. Dueck Ann E. McCullough Monica M. Reinholz Kathleen S. Tenner Nancy E. Davidson Julie Gralow Lyndsay N. Harris Leila A. Kutteh David W. Hillman Robert B. Jenkins Beiyun Chen
- Networks:
- Study
- NCCTG-N9831
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords:
- Brief Communication